GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising

GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million

GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study

GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million

GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million